Melvin Spigelman
Directeur/Membre du Conseil chez AN2 THERAPEUTICS, INC.
Fortune : - $ au 30/06/2024
Profil
Melvin K.
Spigelman is currently the President, Chief Executive Officer & Director at Global Alliance for TB Drug Development since 2009.
He is also the Director at Tres Cantos Open Lab Foundation.
In addition, he serves as an Independent Director at AN2 Therapeutics, Inc. since 2022 and as a Venture Partner at Wellington Partners GmbH since 2005.
Previously, Dr. Spigelman held the position of Chairman at Synergy Pharmaceuticals LLC from 2018 to 2019.
He was an Independent Director at The Medicines Co. from 2005 to 2018.
He also served as Vice President-Global Clinical Centers at Abbott India Ltd.
and Knoll Pharmaceutical Co. from 2000 to 2001.
Additionally, he was the President of Hudson-Douglas Ltd.
in 2003.
He has also worked as an Associate Professor at Icahn School of Medicine at Mount Sinai.
Dr. Spigelman completed his undergraduate degree at Brown University and obtained his doctorate from Icahn School of Medicine at Mount Sinai.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
-.--% | 19/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Melvin Spigelman
| Sociétés | Poste | Début |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/02/2022 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Directeur Général | 01/01/2009 |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 01/01/2005 |
Tres Cantos Open Lab Foundation
 Tres Cantos Open Lab Foundation Miscellaneous Commercial ServicesCommercial Services Tres Cantos Open Lab Foundation provides research facilities for charity. The non-profit company is based in Guildford, UK. | Directeur/Membre du Conseil | - |
Anciens postes connus de Melvin Spigelman
| Sociétés | Poste | Fin |
|---|---|---|
| SYNERGY PHARMACEUTICALS INC | Président | 01/05/2019 |
| THE MEDICINES COMPANY | Directeur/Membre du Conseil | 01/01/2018 |
| Hudson-Douglas Ltd. | President | 01/06/2003 |
| ABBOTT INDIA LIMITED | Directeur Technique/Scientifique/R&D | 01/01/2000 |
| Knoll Pharmaceutical Co. | Directeur Technique/Scientifique/R&D | 01/01/2000 |
Formation de Melvin Spigelman
| Brown University | Undergraduate Degree |
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABBOTT INDIA LIMITED | Health Technology |
| AN2 THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
Synergy Pharmaceuticals LLC
 Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |
| Hudson-Douglas Ltd. | |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
Tres Cantos Open Lab Foundation
Tres Cantos Open Lab Foundation Miscellaneous Commercial ServicesCommercial Services Tres Cantos Open Lab Foundation provides research facilities for charity. The non-profit company is based in Guildford, UK. | Commercial Services |
| Knoll Pharmaceutical Co. |
